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Autologous hematopoietic stem cell transplant
(HSCT) following high-dose melphalan is a standard
treatment for patients with multiple myeloma [1, 2].
Statins (3-Hydroxy-3-MethylGlutaryl-Coenzyme-A
[HMG-CoA] reductase inhibitors) promote apoptosis
when combined with myeloma cell lines in vitro. Van
de Donk et al [3] reported the ability of lovastatin to
increase cytosolic accumulation of rat sarcoma gene
(Ras) by inhibiting its isoprenylation, thereby slowing
myeloma cell proliferation. HMG-CoA reductase is
up-regulated in cell adhesion-mediated drug resistant
(CAM-DR) myeloma cells and when simvastatin is
co-cultured with melphalan, myeloma cells, and stro-
mal cells, CAM-DR is reversed by inhibition of the
Rho-kinase pathway [4]. We theorize that IL-6-de-
pendent myeloma cells [5] that are exposed to statins
will release the second mitochondria-derived activator
of caspases (Smac/DIABLO), leading to activation of
caspases 9, 3, 8, a reduction in Mcl-1 [6], and ulti-
mately apoptosis[7]. Early clinical trials of statins in
myeloma, even at high doses, have produced rare re-
sponses [8,9]. Based on preliminary evidence that sta-
tins may serve as sensitizing agents, we hypothesized
that statin use at the time of autologousHSCTmay in-
crease the response rate to high-dose melphalan. We
present a retrospective review of the impact of con-
comitant statin use on the response and survival of au-
tologous HSCT in patients with multiple myeloma.
One hundred forty-six consecutive patients with
multiple myeloma underwent autologous HSCT after
conditioning with melphalan (200mg/m2 on day -2)
between June 1999 and December 2006 at our institu-
tion. Patients taking statins ($20mg/day) for at least 1
month before and after transplant (n528) were
compared to those without a history of statin use
(n5118). Responses were assessed according to the
International Myeloma Working Group uniform
response criteria [10]. The median age was 58 years
(range 35-74 yrs) with 86 male and 60 female patients.
The 2 groups (as detailed in Table 1) had similar
baseline characteristics including age, serum choles-terol, international stage, number of prior therapies,
and percentage of patients with high-risk cytogenetics
(defined by the presence of t[4;14], t[14;16], deletion
17p, or tetrasomy) (P5.39).
There was a trend towards higher overall response
rate (complete remission [CR] 1 very good partial
response [VGPR] 1 partial response) in the statin
group (93% vs. 78%; P5.07); although the rate of
CR plus VGPR in patients using statins (43%) was
comparable to the CR1 VGPR rate (45%) in patients
not using statins (P5.84). In a subset analysis of
patients with high-risk cytogenetics, the overall
response rate in the statin group (n55) was 100% vs.
78% for non-statin group (n514). Median overall sur-
vival (OS) for the statin vs. non-statin groups were 25.7
and 22 months respectively (P5.65), and the progres-
sion free survivals were 19.5 and 14.8 months respec-
tively (P5.97). Kaplan-Meier estimates of 3 year OS
for statins versus no statins group were 73% and 68%
respectively; 3 year PFS were 32% and 30% respec-
tively. Stem cell mobilization in patients using statins
yielded a mean of 8.3 x 106 CD341 cells/kg versus 6.5
Figure 1. Kaplan-Meier estimates of overall survival (A) and
progression free survival (B) following autologous hematopoietic
stem cell transplantation in patients with multiple myeloma.
Interrupted and solid curves represent patients with and without
statin use, respectively.351
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Statin Group (n528) No statins (n5118)
N (%) N (%)
Median age, years (range) 60 (38-74) 58 (35-72)
Sex
Male 20 (71) 66 (56)
Female 8 (29) 52 (44)
Median number of prior therapies (range) 1 (1-5) 1 (1-4)
Prior Radiation therapy
Yes 9 (32) 34 (29)
No 19 (68) 84 (71)
ISS Stage1
I 11 (39) 53 (45)
II 15 (53) 53 (45)
III 2 (8) 12 (10)
Cytogenetics
High-risk2 5 (18) 14 (12)
Standard-risk 23 (82) 104 (88)
b2-Microglobulin (mg/L), median (range) 2.7 (1.4-6.4) 2.6 (1.1-26.4)
Median CD341 cells infused 8.3 x 106 CD341 cells/kg 6.5 x 106 CD341 cells/kg
Base line Cholesterol (mg/dl) 163 185
Baseline C-reactive protein (mg/L) 5.7 4.9
1ISS indicates International Staging System.
2High-risk cytogenetics were defined by the presence of t[4;14], t[14;16], deletion 17p, or tetraploidy on
a CD138-selected fluorescent in-situ hybridization panel.x 106 CD341 cells/kg in patients not taking statins
(P5.40). No difference was noted in regard tohepatic
toxicity, myositis, infectious complications, or fatal
cardiovascular events.
Patients taking statins at the time of transplanta-
tion showed a trend for a better overall response rate
(93% vs. 78%; P5.07), however, this did not translate
into improved PFS or OS. Our study has several limi-
tations typical of a retrospective study, including selec-
tion and documentation biases. It is possible the
sample size of the study limited the detection of statis-
tically significant difference in ORR between the
2 groups. While we suspect that administering statins
to patients that are statin-naı¨ve at the time of autolo-
gous transplant may be effective, we found no PFS or
OS benefit for patients who had been using statins at
the time of autologous transplant.
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